PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017
Sofosbuvir subsidised in Australia
for hepatitis C
Sofosbuvir (Epclusa) will be subsidised in Australia for
the treatment of hepatitis C from 1 August 2017, via the
Pharmaceutical Benefits Scheme (PBS).
Sofosbuvir is the first of the new direct acting
antivirals that can be used in the treatment of patients
with any genotype of hepatitis and has an expected
success rate of 90%. Up to 200 000 Australians are
infected with hepatitis C, with approximately 800
people dying from the infection each year.
The newly announced government funding will
reduce the treatment cost to the patient to a maximum
of $A38.80 per month, with the concessional price
being just $6.30, compared with unsubsidised costs of
over $20 000 per treatment.
"Eliminating hepatitis C from Australia will take a
coordinated effort from GPs, specialists, nurses, patients
and the Government", commented Minister for Health,
the Hon. Greg Hunt MP. "Today is World Hepatitis Day
and I want to reiterate the Government’s commitment
to eliminate hepatitis C in Australia by 2030".
Over 42 000 Australians have benefited from PBS-
subsidised medicine for chronic hepatitis C since
Australia became one of the first countries in the world
to subsidise new medicines for all adults with chronic
infection. As well as allocating over $1 billion for these
new medicines over the next five years through the PBS,
the Australian government is providing education to
health professionals about hepatitis B and C, as well as
funding hepatitis B vaccination for all infants.
Additionally, free catch-up vaccines became available on
1 July 2017 for all refugees, humanitarian entrants and
10 to 19-year-olds through the National Immunisation
Hon Greg Hunt MP, Minister for Health, Minister for Sport. New drug to help
over 200,000 Australians. Internet Document : 28 Jul 2017. Available from: URL:
PharmacoEconomics & Outcomes News 12 Aug 2017 No. 7841173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved